Alkahest, a subsidiary of Grifols, is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline — key medical challenges of our generation. The company’s breakthrough research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimer’s disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Alkahest is based in San Carlos, Calif., while Grifols, a global healthcare company, is headquartered in Barcelona, Spain.

Company Information

April 19, 2022